Optic Neuropathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Optic Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions.
Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age, smoking, alcohol, cancer treating drugs, stress related chemicals, some antibiotics, and cyanogens.
The Optic Neuropathy drugs in development market research report provide comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Optic Neuropathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 16 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Optic Neuropathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Optic Neuropathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Optic Neuropathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abeona Therapeutics IncAlexandria University
Astellas Pharma Inc
Biocon Ltd
Biozeus Pharmaceutical SA
Healx Ltd
jCyte Inc
Kunshan RiboQuark Pharmaceutical Technology Co Ltd
MyMD Pharmaceuticals Inc
Neurizon Pharma GBR
Neurophoenix
PharmatrophiX Inc
Quark Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Shanghai Jing Ze Biotechnology Co Ltd
University of Auckland
University of Wisconsin Madison
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Optic Neuropathy reports